Journal article
Homocysteine: is it a clinically important cardiovascular risk factor?
Cleveland Clinic journal of medicine, Vol.71(9), pp.729-734
09/2004
DOI: 10.3949/ccjm.71.9.729
PMID: 15478704
Abstract
Elevated plasma homocysteine is associated with an increased risk of myocardial infarction, stroke, and venous thromboembolism. Folic acid and other B vitamins lower plasma homocysteine levels, but whether this therapy confers a clinical benefit has yet to be determined. Until we know the results of ongoing clinical trials of homocysteine-lowering therapy, testing for and treating elevated homocysteine is probably justified only in patients with known cardiovascular disease or who are at high risk.
Details
- Title: Subtitle
- Homocysteine: is it a clinically important cardiovascular risk factor?
- Creators
- Steven R Lentz - Department of Internal Medicine, University of Iowa; Veterans Affairs Medical Center, Iowa CityWilliam G Haynes - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Cleveland Clinic journal of medicine, Vol.71(9), pp.729-734
- DOI
- 10.3949/ccjm.71.9.729
- PMID
- 15478704
- ISSN
- 0891-1150
- eISSN
- 1939-2869
- Grant note
- HL62984 / NHLBI NIH HHS NS24621 / NINDS NIH HHS HL14388 / NHLBI NIH HHS HL58972 / NHLBI NIH HHS HL63943 / NHLBI NIH HHS
- Language
- English
- Date published
- 09/2004
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359955802771
Metrics
27 Record Views